SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

IVVD

Invivyd
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The combination of accelerating revenue growth, improved financial discipline, strong cash position, and rapid clinical progress in the VYD2311 program suggests improved execution and near-term catalyst potential. Traders should monitor for top-line data from the DECLARATION trial in mid-2026 and any trial resizing decision in April 2026.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.74
T+0 close · Mar 5, 2026 · via day close
Latest settled
−29.89%
T+60 · $1.22
Vs SPY
−41.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $1.74entry
  2. T+1 · 9mo ago +3.45%α +4.76% · $1.80
  3. T+5 · 8mo ago +3.45%α +5.69% · $1.80
  4. T+20 · 8mo ago −26.44%α −22.65% · $1.28
  5. T+60 · 6mo ago −29.89%α −41.19% · $1.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invivyd reported strong Q4 and full-year 2025 financial results with PEMGARDA net product revenue of $17.2 million (up 25% YoY) and full-year revenue of $53.4 million (up 110% YoY), while significantly reducing R&D expenses to $38.3 million from $137.3 million. The company ended 2025 with $226.7 million in cash after raising over $200 million, supporting its pivotal DECLARATION Phase 3 trial for VYD2311 with top-line data expected mid-2026.

Key Financial Metrics

Revenue
$53.4M
+110.0% YoY
EPS
$-0.30

Key Facts

  • Q4 2025 PEMGARDA net revenue: $17.2M, up 25% YoY and 31% QoQ
  • Full-year 2025 PEMGARDA net revenue: $53.4M, up 110% from $25.4M in 2024
  • R&D expenses dropped to $38.3M in 2025 from $137.3M in 2024
  • Cash and cash equivalents: $226.7M as of Dec 31, 2025, after raising over $200M in 2H 2025
  • Net loss narrowed to $52.5M in 2025 from $169.9M in 2024; EPS improved to -$0.30 from -$1.43
  • Full enrollment achieved in DECLARATION Phase 3 trial for VYD2311; top-line data expected mid-2026
  • FDA granted Fast Track designation for VYD2311 in December 2025
  • IDMC recommended expansion of trial to include pregnant and breastfeeding women

Financial Impact

Revenue more than doubled year-over-year to $53.4M with significant cost reductions, leading to a 69% reduction in net loss. Cash position of $226.7M supports clinical development into 2026+.

revenuer_and_d_expensenet_lossepscash

Risk Factors

  • VYD2311 remains investigational; clinical trial outcomes are uncertain
  • Revenue is currently limited to EUA status for PEMGARDA, which could be revoked
  • High cash burn in prior periods; future financing may be needed depending on VYD2311 commercialization plans

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250025

Track record

19 reports on IVVD

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
  2. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
  3. Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
  5. Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
  6. Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
  7. Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
  8. Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
  10. Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026